ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,988,000 | -61.4% | 115,820 | -20.0% | 0.29% | -62.8% |
| Q4 2020 | $7,737,000 | +27.9% | 144,720 | -1.3% | 0.78% | +15.7% |
| Q3 2020 | $6,048,000 | -13.6% | 146,620 | +1.6% | 0.68% | -21.1% |
| Q2 2020 | $6,998,000 | +12.2% | 144,370 | -2.2% | 0.86% | -6.9% |
| Q1 2020 | $6,235,000 | -1.2% | 147,570 | +0.1% | 0.92% | +25.1% |
| Q4 2019 | $6,309,000 | +1.1% | 147,470 | -0.1% | 0.74% | -7.7% |
| Q3 2019 | $6,239,000 | +49.4% | 147,640 | -5.5% | 0.80% | +47.6% |
| Q2 2019 | $4,177,000 | -2.4% | 156,280 | -1.9% | 0.54% | -4.3% |
| Q1 2019 | $4,278,000 | +24.6% | 159,330 | +2.6% | 0.56% | +17.0% |
| Q4 2018 | $3,433,000 | -10.0% | 155,330 | -15.5% | 0.48% | +2.3% |
| Q3 2018 | $3,816,000 | +35.5% | 183,830 | -0.4% | 0.47% | +26.3% |
| Q2 2018 | $2,817,000 | -40.4% | 184,510 | -12.3% | 0.37% | -37.1% |
| Q1 2018 | $4,727,000 | -21.7% | 210,390 | +5.0% | 0.59% | -18.9% |
| Q4 2017 | $6,036,000 | – | 200,460 | – | 0.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |